Novartis Drug Discovery Centralization Brings R&D Relocations, Job Cuts
Novartis' efforts to rationalize and centralize its drug discovery programs will see the Novartis Institute for Tropical Diseases moved from Singapore to California and the closure of biologics units in Shanghai and in the Swiss town of Schlieren.
You may also be interested in...
The head of Novartis' early drug discovery engine NIBR has a zealous sense of mission and says he is being given the resources and talent to accomplish it. "Nothing is undruggable," is his premise.
Life science and pharma companies have been actively investing in Asia over the past month as they look to increase regional manufacturing capacities to tap into burgeoning markets and meet rising demand for new technologies, biologics and high-quality products, while Chinese firms have also been expanding their international presence.
Novartis is closing its high-profile cell and gene therapy unit – the one responsible for developing CAR-T therapies. The move suggests Novartis’s outlook for the CAR-T field may be changing, though it’s not clear why.